Journal
STROKE
Volume 40, Issue 3, Pages S90-S91Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/STROKEAHA.108.533125
Keywords
deferoxamine; ICH; edema; neuroprotection
Categories
Funding
- National Institutes of Health/National Institute of Neurological Diseases and Stroke [1R01-NS 057127-01A1, 1R01-NS 045754-01A2, 5R01-HL46690-14]
Ask authors/readers for more resources
Iron resulting from hemoglobin degradation is linked to delayed neuronal injury after intracerebral hemorrhage. Extensive preclinical investigations indicate that the iron chelator, deferoxamine mesylate, is effective in limiting hemoglobin- and iron-mediated neurotoxicity. However, clinical studies evaluating the use of deferoxamine in intracerebral hemorrhage are shortcoming. This article reviews the potential role of deferoxamine as a promising neuroprotective agent to target the secondary effects of intracerebral hemorrhage to limit brain injury and improve outcome, and ongoing efforts to translate the preclinical findings into clinical investigations. (Stroke. 2009; 40[suppl 1]: S90-S91.)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available